Wednesday, July 8, 2026

biotech · Duchenne Muscular Dystrophy · Duchenne muscular dystrophy · SLDB

Solid Biosciences

Solid Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker SLDB. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne muscular dystrophy, Glioblastom

500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US HQ
2013 Founded
155 Employees
Public company Type
SLDB · NYSE Ticker
Company details
Status
Public
HQ
500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
Founded
2013
Employees
155
Programs
16
Drugs
20
Patents
2
Clinical program

filgrastim

Phase 3 · mab · Lung Cancer

filgrastim for Lung Cancer is a Phase 3 program (mab) at Solid Biosciences with 1 ClinicalTrials.gov record(s).

Internal code CDR0000068379

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Solid Biosciences
Phase
Phase 3
Modality
mab
Indication
Lung Cancer
Status
active
Trials
1